Brunner, PhilippePhilippeBrunnerJörg, Ann-CatherineAnn-CatherineJörgGlatz, KatharinaKatharinaGlatzBubendorf, LukasLukasBubendorfRadojewski, PiotrPiotrRadojewskiUmlauft, MariaMariaUmlauftMarincek, NicolasNicolasMarincekSpanjol, Petar MarkoPetar MarkoSpanjolKrause, Thomas MichaelThomas MichaelKrause0000-0002-3659-001XDumont, Rebecca ARebecca ADumontMaecke, Helmut RHelmut RMaeckeMüller-Brand, JanJanMüller-BrandBriel, MatthiasMatthiasBrielSchmitt Kurrer, AnjaAnjaSchmitt KurrerPerren, AurelAurelPerren0000-0002-6819-6092Walter, Martin AlexanderMartin AlexanderWalter0000-0001-6487-53492024-10-242024-10-242017-03https://boris-portal.unibe.ch/handle/20.500.12422/149043PURPOSE Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr2) in neuroendocrine tumors (NETs). METHODS We established a tissue microarray and imaging database from NET patients that received sstr2-targeted radiopeptide therapy with yttrium-90-DOTATOC, lutetium-177-DOTATOC or alternative treatment. We used univariate and multivariate analyses to identify prognostic and predictive markers for overall survival, including sstr2-imaging and sstr2-immunohistochemistry. RESULTS We included a total of 279 patients. In these patients, sstr2-immunohistochemistry was an independent prognostic marker for overall survival (HR: 0.82, 95 % CI: 0.67 - 0.99, n = 279, p = 0.037). In DOTATOC patients, sstr2-expression on immunohistochemistry correlated with tumor uptake on sstr2-imaging (n = 170, p < 0.001); however, sstr2-imaging showed a higher prognostic accuracy (positive predictive value: +27 %, 95 % CI: 3 - 56 %, p = 0.025). Sstr2-expression did not predict a benefit of DOTATOC over alternative treatment (p = 0.93). CONCLUSIONS Our results suggest sstr2 as an independent prognostic marker in NETs. Sstr2-immunohistochemistry correlates with sstr2-imaging; however, sstr2-imaging is more accurate for determining the individual prognosis.enIndividualized therapyMetabolic therapyPRRTTailored therapyTargeted therapy500 - Science::570 - Life sciences; biology600 - Technology::610 - Medicine & healtharticle10.7892/boris.943262753902010.1007/s00259-016-3486-2